麻豆传媒

Undetectable MRD rates of 90% or higher, PFS of 7 years or more

All-trans retinoic acid plus arsenic trioxide and idarubicin improved EFS over standard

Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation?

ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment

Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil

Better response rates and survival with axicabtagene ciloleucel versus external control group

Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor

Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone

Anti-CD38 therapy added to conventional regimen boosts PFS in trial

Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases

Triplet regimen significantly extended median PFS versus doublet in IKEMA study

More quizartinib-treated patients went on to stem cell transplant

Preexisting aberrant B-cell clone implicated

Progression-free survival doubled with carfilzomib versus bortezomib